XX% the across U.S. quarter Doug. across a doubled The strong U.S. products posted was all last from business. beds. once International from our coronary, usage was and Growth and another peripheral up team vessel again year you, revenue ago. three solid quarter by Thank and peripheral U.S. driven almost peripheral
the very launch. fully In to MX+, encouraging below-the-knee the and have business to MX+ are SX steadily have transitioned increased increasingly early start off and U.S., with we to LX a
Our for strategy other LX consistent for our with launch product what has worked launches. is
We very accounts when deliberate to to launch that understand a LX. customers help ensure where manner and use expect to controlled, in
of our other LX products. reinforce We plan launch to period to use appropriate also the use
peripheral treat common arteries. the to specifically iliac of designed is vessels LX larger femoral and
Our emitter developing lesions to to other energy distinct able our from more delivery engineers high large of compact is by a were that vessel uniform achieve array products. a profile these
the diameter. vessel the to larger able profile, energy better balloons the In to energy facilitate addition are target diameter up improved delivery to and dilate
the clinical impressed in practice are we and are are results surprising are physicians as results it that we stented. looks as our after The good how angiographic artery customers. What in is cases us most many the often LX, noting if with hearing
that we not clinical X into millimeters the with seeing We see and sizes. six procedures incremental new XX some the cases the utility address. MX+ XX% offered, our could are millimeters, About across and optimally XX suggesting utilization strong that millimeters, are are from coming of sizes penetration may pleased
value strong clinical to a addition In economic proposition a value for LX strong hospitals. proposition, carries
clinically is for devices. IVL arteries, many the this whereas in is First, indicated case iliac atherectomy the for of not use
reimbursement not cost adequately in LX. covers that hospital acquire Second, arteries atherectomy. iliac consistent carries additional contrast, is In for IVL reimbursement to
a a U.S. penetration QX sequentially XX% into from by QX sequentially our daily driven year solid XX% the to coronary from compared accounts. XX% from prior Average XX% revenue grew and increased increased sales and year. ago, existing primarily
that our are business QX added strong account new new in XX year last coronary the key activities succeeding. the anticipated, The sign of accounts is quarter. continue only in we as decline about we second As first to in in initiated a additions the growth U.S. half
coronary penetration launched able nearly were to XXXX U.S. XX% of accounts coronary accounts, revenue of XXXX. We our in the coming from QX have with that increase before been IVL
take of believe you remind I to have a IVL. penetration coronary will the drive just that worked activities minute to we of deeper
X.X territories XX this the we throughout to structure, specialist territory. increasing continue the territories -- per per clinical and we quarter optimizing and territory specialists our First, adding added about plan year. We the ended clinical with
using them enables strategy they this penetration both physicians more and when IVL. help time spends in drives then Together, hospitals should to and team peripheral. with appropriately reinforce for time train coronary increased the spend be our us The to
with markets. our for in newly-launched posted start products, results we a catheter. of Sales International grew side, XX% coronary both our the solid almost year-ago that our was and over ago strong CX+ had of On all International a we and record peripheral year revenue double from performance
efforts foster marketing that have KOLs is supported focused now Peripheral as education. are by have resources to We our growing peer-to-peer very momentum substantially. increased internationally we
launches far. getting Similar high encouraged our a have accounts, volume team but targeting to LX the the the educating methodical seen launch, time early is very spending and feedback each deeper our they are It the strategy follows is so other going CX+ of execute, into us about you launch and launch account.
the with particularly in IVL have Germany, combined In reimburse procedures saw Japan. game-changer growth few launch Germany and the higher been CX+ change first we in coronary of coronary the in businesses a to strong paying Geographically, months. at for our January DRGs
know, are prior you Germany As represented penetration market most the and hospitals direct which IVL to negative coronary by country. being other and Despite of German only X%, on in team, year. economics far January cases lower was on very being is European Western sales strong nearly this about than years five IVL is a for in margin focused any
expand to in to look We go in the that the European and Western educate amongst of the penetration expect Germany countries. we to our our team better use lowest forward growth on physicians IVL. continued highest I service will Germany from as
is launch well. very Japan Our in going
plan by with enthusiastic in IVL propelled additional professionals further seeing and that We high-volume to team adding reps, continue use and physician already to marketing accounts in sales Japan. our in support functions field launched are strong solid We centers adoption of support. penetration accelerate building
success this markets are by where for encouraged teams achieving economic early IVL our well Japan, year in are and considerations We are is Germany adequate reimbursement addressed. and the
to indicator We IVL penetration focus this U.S. long-term for coronary over is into reimbursement the believe year. increases in the beginning picture a this come positive as potential for course the of in is
in reimbursement hope setting. XXXX of do. have and we long-term CMS then, device coronary the IPPS they inpatient when for to we proposed TPT outpatient cost. XXXX This the about remain We the in the hospital’s IVL picture bullish chooses seen in first readout rules addressing hospital three setting covers address the Until summer, the U.S. with
will we This our We CMS those see also enable new will IVL physicians. know that for any summer, propose payment time receive for physicians the incremental payment of a for CPT to what will therapies. coronary incremental for first code
this physician goal, work of better the and payment the We environment IVL. and a have PCI, their shares very to physician for an the are patient aligned. receiving The incentives safe to ensure patient, particularly IVL are all The result. additional using the is have worked treatment where incremental create for for when because helps goal hospital for it’s calcified they
when patients is the wants have further the the and best therapy hospital motivated procedures to positive get economics. The
what early We of incentives are seen we have rates can early and thus aligned these have penetration Japan. encouraging evidence in very be far all when IVL adoption from the
the With that, I to Trinh to financials. will turn review the call
